Curated News
By: NewsRamp Editorial Staff
July 30, 2026
Lexaria Bioscience Announces Reverse Stock Split to Regain Nasdaq Compliance
TLDR
- Lexaria's reverse split aims to regain Nasdaq compliance, stabilizing stock price and attracting investors.
- Lexaria will reverse split shares 1-for-15 to increase price, adjust authorized shares and convertible securities accordingly.
- By stabilizing its stock, Lexaria secures Nasdaq listing, enabling continued innovation in drug delivery technology.
- Lexaria's reverse split ratio of 1-for-15 is below the average 1-for-18 for recent Nasdaq biotech splits.
Impact - Why it Matters
This reverse stock split is critical for Lexaria's continued Nasdaq listing, which directly impacts its ability to attract partners and investors, and ultimately the commercialization of its DehydraTECH drug delivery technology. For shareholders, it aims to stabilize the stock price and prevent delisting, preserving their investment and the company's access to capital markets.
Summary
Lexaria Bioscience Corp. (Nasdaq: LEXX) has announced a 1-for-15 reverse stock split, effective August 3, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price per share requirement. The company, a global innovator in drug delivery platforms, is taking this proactive step to stabilize its stock price and continue its listing on the Nasdaq Capital Market. CEO Richard Christopher emphasized that Nasdaq compliance is crucial for attracting business development partners and broadening investor appeal. The reverse split will reduce the issued share capital from 24,787,446 to approximately 1,652,518 shares, with fractional shares rounded up. This move follows an analysis of 24 other reverse splits by Nasdaq-listed biotech firms, where the average ratio was 1-for-18. Lexaria anticipates meeting the Minimum Price Rule by mid-August and will request a Nasdaq hearing if needed.
Lexaria's patented DehydraTECH™ platform, which enhances oral drug delivery and blood-brain barrier penetration, is at the core of its technology. The company holds 66 patents globally and operates a licensed in-house research lab. The reverse split does not change the proportional ownership for shareholders, and the stock will continue trading under LEXX with a new CUSIP number. Shareholders with physical certificates must contact Computershare Trust Company of Canada for adjustments. This strategic move aims to provide a stable foundation for Lexaria to capitalize on upcoming opportunities, despite recent equity market weakness that the CEO believes is at odds with the company's potential.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Lexaria Bioscience Announces Reverse Stock Split to Regain Nasdaq Compliance
